Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 77% Improvement Relative Risk Mortality (b) 65% Mortality (c) 67% Mortality (d) 58% Hospitalization -33% Hospitalization (b) -13% Hospitalization (c) -100% Hospitalization (d) 58% Viral clearance 49% Viral clearance (b) 89% Viral clearance (c) 30% Viral clearance (d) -9% Viral clearance (e) 92% Viral clearance (f) 92% Viral clearance (g) 91% Viral clearance (h) 59% Viral clearance (i) 30% Viral clearance (j) 62% Viral clearance (k) -8% Viral clearance (l) 56% c19early.org/m Fischer et al. NCT04405570 Molnupiravir RCT EARLY Is early treatment with molnupiravir beneficial for COVID-19? RCT 202 patients in the USA Lower mortality (p=0.31) and improved viral clearance (p=0.12), not stat. sig. Fischer et al., medRxiv, doi:10.1101/2021.06.17.21258639 Favors molnupiravir Favors control
Molnupiravir, an Oral Antiviral Treatment for COVID-19
Fischer et al., medRxiv, doi:10.1101/2021.06.17.21258639 (Preprint), NCT04405570 (history)
Fischer et al., Molnupiravir, an Oral Antiviral Treatment for COVID-19, medRxiv, doi:10.1101/2021.06.17.21258639 (Preprint), NCT04405570
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 202 outpatients in the USA showing significantly faster viral clearance, but no significant differences in symptom duration or severity. NCT04405570 (history).
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir.
risk of death, 76.5% lower, RR 0.23, p = 0.31, treatment 0 of 140 (0.0%), control 1 of 62 (1.6%), NNT 62, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), all.
risk of death, 65.4% lower, RR 0.35, p = 1.00, treatment 0 of 55 (0.0%), control 1 of 62 (1.6%), NNT 62, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 800mg.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 62 (0.0%), control 1 of 62 (1.6%), NNT 62, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 400mg.
risk of death, 57.8% lower, RR 0.42, p = 1.00, treatment 0 of 23 (0.0%), control 1 of 62 (1.6%), NNT 62, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 200mg.
risk of hospitalization, 32.9% higher, RR 1.33, p = 1.00, treatment 3 of 140 (2.1%), control 1 of 62 (1.6%), all.
risk of hospitalization, 12.7% higher, RR 1.13, p = 1.00, treatment 1 of 55 (1.8%), control 1 of 62 (1.6%), 800mg.
risk of hospitalization, 100% higher, RR 2.00, p = 1.00, treatment 2 of 62 (3.2%), control 1 of 62 (1.6%), 400mg.
risk of hospitalization, 57.8% lower, RR 0.42, p = 1.00, treatment 0 of 23 (0.0%), control 1 of 62 (1.6%), NNT 62, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 200mg.
risk of no viral clearance, 49.2% lower, RR 0.51, p = 0.12, treatment 10 of 118 (8.5%), control 9 of 54 (16.7%), NNT 12, infectious, day 3, all.
risk of no viral clearance, 88.7% lower, RR 0.11, p = 0.02, treatment 1 of 53 (1.9%), control 9 of 54 (16.7%), NNT 6.8, infectious, day 3, 800mg.
risk of no viral clearance, 30.2% lower, RR 0.70, p = 0.57, treatment 5 of 43 (11.6%), control 9 of 54 (16.7%), NNT 20, infectious, day 3, 400mg.
risk of no viral clearance, 9.1% higher, RR 1.09, p = 1.00, treatment 4 of 22 (18.2%), control 9 of 54 (16.7%), infectious, day 3, 200mg.
risk of no viral clearance, 92.3% lower, RR 0.08, p = 0.004, treatment 1 of 117 (0.9%), control 6 of 54 (11.1%), NNT 9.8, infectious, day 5, all.
risk of no viral clearance, 92.2% lower, RR 0.08, p = 0.03, treatment 0 of 53 (0.0%), control 6 of 54 (11.1%), NNT 9.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), infectious, day 5, 800mg.
risk of no viral clearance, 91.4% lower, RR 0.09, p = 0.03, treatment 0 of 42 (0.0%), control 6 of 54 (11.1%), NNT 9.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), infectious, day 5, 400mg.
risk of no viral clearance, 59.1% lower, RR 0.41, p = 0.67, treatment 1 of 22 (4.5%), control 6 of 54 (11.1%), NNT 15, infectious, day 5, 200mg.
risk of no viral clearance, 29.5% lower, RR 0.70, p = 0.30, treatment 19 of 137 (13.9%), control 12 of 61 (19.7%), NNT 17, all.
risk of no viral clearance, 61.6% lower, RR 0.38, p = 0.10, treatment 4 of 53 (7.5%), control 12 of 61 (19.7%), NNT 8.2, 800mg.
risk of no viral clearance, 8.3% higher, RR 1.08, p = 1.00, treatment 13 of 61 (21.3%), control 12 of 61 (19.7%), 400mg.
risk of no viral clearance, 55.8% lower, RR 0.44, p = 0.33, treatment 2 of 23 (8.7%), control 12 of 61 (19.7%), NNT 9.1, 200mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fischer et al., 18 Jun 2021, Randomized Controlled Trial, USA, preprint, 18 authors, average treatment delay 4.6 days, trial NCT04405570 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21258639; this version posted June 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Molnupiravir, an Oral Antiviral Treatment for COVID-19 William Fischer, MD, Institute for Global Health and Infectious Disease, Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Joseph J. Eron Jr, MD, Department of Medicine, Division of Infectious Diseases, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Wayne Holman, MD, Ridgeback Biotherapeutics LP, Miami, FL, USA. Myron S. Cohen, MD, Institute for Global Health and Infectious Disease, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Lei Fang, MS, Pharstat Inc., Raleigh, NC, USA Laura J. Szewczyk, BS, Ridgeback Biotherapeutics LP, Miami, FL, USA. Timothy P Sheahan, PhD, Department of Epidemiology, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Ralph Baric, Department of Epidemiology, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Katie R. Mollan, MS, Gillings School of Global Public Health, School of Medicine, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Cameron R. Wolfe, MBBS MPH, Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21258639; this version posted June 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Elizabeth R. Duke, MD MA, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. Masoud M. Azizad, MD, Valley Clinical Trials, Inc., Northridge, CA, USA. Katyna Borroto-Esoda, MS, KBE Consulting, Raleigh, NC, USA. David A. Wohl, MD, Institute for Global Health and Infectious Disease, Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Amy James Loftis, BSc, Institute for Global Health and Infectious Disease, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Paul Alabanza, BSc, Lineberger Comprehensive Cancer Center, The University of North Carolina and Chapel Hill, Chapel Hill, NC, USA. Felicia Lipansky, Ridgeback Biotherapeutics LP, Miami, FL, USA. Wendy P. Painter, MD MPH, Ridgeback Biotherapeutics LP, Miami, FL, USA. Corresponding author: Wendy P. Painter, MD, MPH, Ridgeback Biotherapeutics, Miami, FL, USA. Abstract Background: Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a 2 medRxiv preprint doi: https://doi.org/10.1101/2021.06.17.21258639; this version posted June 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit